UNSPSC 51385803: Lornoxicam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H10ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ER09126G7A, chemically known as 6-chloro-4-hydroxy-2-methyl-n-2-pyridyl-2h-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide but generally known as lornoxicam, which bears US NIH Compound Identifier 5282204. European Medicines Agency schedules Lornoxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08589MIG.

UNSPSC 51385803 Lornoxicam is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent opportunities tagged under it span a broader range of pharmacy-related acquisitions including naloxone, over-the-counter products, and direct-to-manufacturer prescription programs rather than the nonsteroidal anti-inflammatory drug implied by the code name alone. State and local issuers using this code include county health departments, state health and human services agencies, and cooperative purchasing consortia. Seminole County, Florida recently issued an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, while the Texas Health and Human Services Commission posted an RFI to gather vendor capabilities for implementing a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, released an RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities including Oregon, requiring vendors to work through three authorized wholesalers and certify cGMP and Drug Supply Chain Security Act compliance.

Recent activity shows geographic spread across Florida, Texas, and the Upper Midwest, with MMCAP's multi-state framework reaching across state lines. Seminole County's naloxone and drug deactivation systems IFB (IFB60459723LAS) required bids by July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford, and included a probationary three-month term and potential FEMA funding with associated federal compliance requirements. The Texas HHS RFI (HHS0017013) closed April 3, 2026, as a preliminary market-intelligence tool designed to inform future formal solicitations, soliciting vendor experience with direct contracting for self-insured employers and outcomes-based pricing models. The MMCAP RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products required proposals by March 26, 2026, with awarded contracts effective July 1, 2026, and weighted evaluation heavily toward price competitiveness (75 percent), cGMP and DSCSA compliance, contractual relationships with authorized wholesalers, and insurance requirements including $5 million commercial general liability and $2 million network security and privacy liability coverage.